# Influenza, Human FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/influenza-human

> 4 upcoming FDA catalysts in influenza, Human: mrna seasonal flu vaccine (GSK) on Jul to Oct 2027 (topline data readout); mrna seasonal flu vaccine (GSK) on July 2027 (primary completion); mrna seasonal flu vaccine (GSK) on Jun to Sep 2028 (topline data readout); mrna seasonal flu vaccine (GSK) on June 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 11, 2026 | [Flu mrna (formulation a) primary completion](https://sec-api.dev/pdufa/flu-mrna-formulation-a) | GSK | Influenza, Human | completed | "NCT07121192 (A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07121192)) |
| August 24, 2026 | [Flu mrna (formulation b1) primary completion](https://sec-api.dev/pdufa/flu-mrna-formulation-b1) | GSK | Influenza, Human | completed | "NCT07204964 (A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-24 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204964)) |
| Aug to Nov 2026 | [Flu mrna (formulation b1) topline data readout](https://sec-api.dev/pdufa/flu-mrna-formulation-b1) | GSK | Influenza, Human | scheduled | "NCT07204964 (A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-24 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204964)) |
| Jul to Oct 2027 | [Mrna seasonal flu vaccine topline data readout](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07851246 (A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07851246)) |
| July 2027 | [Mrna seasonal flu vaccine primary completion](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07851246 (A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07851246)) |
| Jun to Sep 2028 | [Mrna seasonal flu vaccine topline data readout](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07805707 (A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07805707)) |
| June 2028 | [Mrna seasonal flu vaccine primary completion](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07805707 (A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07805707)) |

## Drugs

- [Flu mrna (formulation a)](https://sec-api.dev/pdufa/flu-mrna-formulation-a) (GSK)
- [Flu mrna (formulation b1)](https://sec-api.dev/pdufa/flu-mrna-formulation-b1) (GSK)
- [Mrna seasonal flu vaccine](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/influenza-human.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Influenza, Human FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/influenza-human

```bibtex
@misc{secapidev_indications_influenza_human_20261116,
  title        = {Influenza, Human FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/influenza-human}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_influenza_human_20261116","title":"Influenza, Human FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/influenza-human","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
